Significant association of PRAME expression has also been reported in ALL (17-42%) [18,19], CLL (27%) [11,20], myeloma (23-52%) [21,22] and chronic phase CML (36%) [12]. This evidence concerns the gene PRAME and chronic myelogenous leukemia, BCR-ABL1 positive.